GM-CSF Protein

Produktnummer ABIN7318085

Dieses Recombinant GM-CSF-Protein wird in HEK-293 Cells exprimiert.

Kurzübersicht für GM-CSF Protein (ABIN7318085)

Target: GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

Protein-Typ: Recombinant

Biologische Aktivität: Active

Spezies: Human

Quelle: HEK-293 Cells

Applikation: Cell Culture (CC)

Reinheit: > 90 % as determined by reducing SDS-PAGE.

Produktdetails

Verwendungszweck: Recombinant Human GM-CSF/CSF2 Protein (HEK293 Cells)

Sequenz: Met 1-Glu144

Produktmerkmale: A DNA sequence encoding human GMCSF (NP_000749.2) (Met1-Glu144) was expressed.

Sterilität: 0.2 μm filtered

Endotoxin-Niveau: < 1.0 EU per μg of the protein as determined by the LAL method.

Biological Activity Comment: Measured in a cell proliferation assay using TF-1 human erythroleukemic cells. The ED₅₀ for this effect is typically 0.1-0.6 ng/ml.

Anwendungsinformationen

Applikationshinweise: Optimal working dilution should be determined by the investigator.

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Buffer: Lyophilized from sterile PBS, pH 7.4.
Normally 5 % - 8 % trehalose, mannitol and 0.01 % Tween 80 are added as protectants before lyophilization.

Lagerung: 4 °C,-20 °C,-80 °C

Informationen zur Lagerung: Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of reconstituted samples are stable at < -20°C for 3 months.

Haltbarkeit: 12 months

Antigendetails

Target: GM-CSF (CSF2) (Colony Stimulating Factor 2 (Granulocyte-Macrophage) (CSF2))

Andere Bezeichnung: GM-CSF/CSF2

Hintergrund: CSF,CSF2,Colony-Stimulating Factor,GM-CSF,GMCSF,Granulocyte-Macrophage Colony-Stimulating Factor,Molgramostin,Sargramostim,Granulocyte-macrophage colony-stimulating factor (GM-CSF) is one of an array of cytokines with pivotal roles in embryo implantation and subsequent development. Several cell lineages in the reproductive tract and gestational tissues synthesise GM-CSF under direction by ovarian steroid hormones and signalling agents originating in male seminal fluid and the conceptus. The pre-implantation embryo, invading placental trophoblast cells and the abundant populations of leukocytes controlling maternal immune tolerance are all subject to GM-CSF regulation. GM-CSF stimulates the differentiation of hematopoietic progenitors to monocytes and neutrophils, and reduces the risk for febrile neutropenia in cancer patients. GM-CSF also has been shown to induce the differentiation of myeloid dendritic cells (DCs) that promote the development of T-helper type 1 immune responses in cognate T cells. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has been utilized in the clinical management of multiple disease processes. Most recently, GM-CSF has been incorporated into the treatment of malignancies as a sole therapy, as well as a vaccine adjuvant. While the benefits of GM-CSF in this arena have been promising, recent reports have suggested the potential for GM-CSF to induce immune suppression and, thus, negatively impact outcomes in the management of cancer patients.

Molekulargewicht:

Calculated MW: 14.5 kDa

Observed MW: 23.8 kDa

Gen-ID: 1437

NCBI Accession: NP_000749

UniProt: P04141

Pathways: JAK-STAT Signalweg, Cellular Response to Molecule of Bacterial Origin